Nanotechnology Now - Press Release: Arrowhead to Present at Oppenheimer 21st Annual Healthcare Conference

Home > Press > Arrowhead to Present at Oppenheimer 21st Annual Healthcare Conference

Abstract:
Arrowhead Research Corporation (ARWR 1.02, 0.00, 0.00%) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Oppenheimer 21st Annual Healthcare Conference at 10:50 a.m. ET on Tuesday, November 2, 2010, at the Waldorf-Astoria Hotel in New York City, NY. Dr. Anzalone plans to provide a corporate summary and update on the Company's progress.

Arrowhead to Present at Oppenheimer 21st Annual Healthcare Conference

Pasadena, CA | Posted on October 26th, 2010

Dr. Anzalone will also host one-on-one meetings with members of the professional community in New York on November 3-4, 2010. Professional investors can schedule a meeting with Dr. Anzalone by contacting Brandi Floberg at 212-481-2050 or Those investors attending the conference are encouraged to sign up to meet with Dr. Anzalone at the conference through their Oppenheimer sales representative.

Over more than 20 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. The conference will include a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (ARWR 1.02, 0.00, 0.00%) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries: Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.

For more information, please click here

Contacts:
The Piacente Group
Brandi Floberg, 212-481-2050

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: